Skip to Main Content

Author Details

Arndt Vogel
Clinic for Gastroenterology, Medical University Hannover
2001
279
56
PMIDPaper TitleJournal TitlePublished Year
37996507Efficacy and quality of life for FOLFOX/bevacizumab +/- irinotecan in first-line metastatic colorectal cancer-final results of the AIO CHARTA trial.Br J Cancer2024
36166092Study protocol: the OptiScreen-Study: optimized psycho-oncological care-from screening to intervention.J Cancer Res Clin Oncol2023
37708457Validation and optimization of AFP-based biomarker panels for early HCC detection in Latin America and Europe.Hepatol Commun2023
37796513Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial.JAMA Oncol2023
37901766Albumin-Bilirubin Grade Analyses of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study.Liver Cancer2023
37901764Survival Trends in Sorafenib for Advanced Hepatocellular Carcinoma: A Reconstructed Individual Patient Data Meta-Analysis of Randomized Trials.Liver Cancer2023
37746835Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer.Future Oncol2023
37615958Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.JAMA Oncol2023
37585204Patterns in Cancer Incidence Among People Younger Than 50 Years in the US, 2010 to 2019.JAMA Netw Open2023
38058419Atezolizumab in Combination with Bevacizumab for the Management of Patients with Hepatocellular Carcinoma in the First-Line Setting: Systematic Literature Review and Meta-Analysis.Liver Cancer2023
37680945Effectiveness and safety of atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis.EClinicalMedicine2023
37817754Predictive and Prognostic Potential of Liver Function Assessment in Patients with Advanced Hepatocellular Carcinoma: A Systematic Literature Review.Liver Cancer2023
35788059Genetic variation in <i>TERT</i> modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: results from a genome-wide case-control study.Gut2023
37291403Should I call psycho-oncology? Training nurses on psycho-oncological screening reduces uncertainties.J Cancer Res Clin Oncol2023
37351572A critical spotlight on the paradigms of FFPE-DNA sequencing.Nucleic Acids Res2023
37086920Aetiology of liver disease and response to immune checkpoint inhibitors: An updated meta-analysis confirms benefit in those with non-viral liver disease.J Hepatol2023
37452405Heparin reversal with protamine sulfate after Percutaneous Hepatic Perfusion (PHP): is less more?Cancer Imaging2023
37040776S3-Leitlinie Diagnostik und Therapie biliärer Karzinome ⿿ Langversion.Z Gastroenterol2023
37007632Adjuvant therapy of biliary tract cancers.Ther Adv Med Oncol2023
37005953Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma.Hepatol Int2023
36753993Clinical characteristics and outcome of patients with combined hepatocellular-cholangiocarcinoma-a European multicenter cohort.ESMO Open2023
36588300Immune checkpoint inhibitors in malignancies after liver transplantation: Better safe or sorry?Liver Int2023
36587472Chemosaturation for primary and secondary liver malignancies: A comprehensive update of current evidence.Cancer Treat Rev2023
36807338'Potentially curative therapies' for hepatocellular carcinoma: how many patients can actually be cured?Br J Cancer2023
36577703Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study.Liver Int2023
36865801Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors.Front Oncol2023
36528236Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma.J Hepatol2023
36417096New perspectives in unresectable cholangiocarcinoma? Evaluation of chemosaturation with percutaneous hepatic perfusion as a palliative treatment option.Clin Exp Metastasis2023
36341767Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study.J Hepatol2023
36108710Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma.Gastroenterology2023
36170665FGFR2 Inhibition in Cholangiocarcinoma.Annu Rev Med2023
34648895Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score.J Hepatol2022
35397937Corrigendum to 'Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model' [J Hepatol (2021) 1420-1433].J Hepatol2022
35601131Performance evaluation of the Elecsys PIVKA-II and Elecsys AFP assays for hepatocellular carcinoma diagnosis.JGH Open2022
35364421Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.Eur J Cancer2022
35421228Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial.Clin Cancer Res2022
35655320A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors.J Exp Clin Cancer Res2022
36462464Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations.ESMO Open2022
36497316Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab.Cancers (Basel)2022
36148739Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study.Eur J Cancer2022
35871236Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing.Br J Cancer2022
36037792Cabozantinib after prior checkpoint inhibitor therapy in patients with solid tumors: A systematic literature review.Cancer Treat Rev2022
36098320Second-line therapy with nivolumab plus ipilimumab for older patients with oesophageal squamous cell cancer (RAMONA): a multicentre, open-label phase 2 trial.Lancet Healthy Longev2022
35986902Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma.Liver Int2022
35922562Predictive Parameters in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan for Unresectable Liver Metastases from Uveal Melanoma: A Retrospective Pooled Analysis.Cardiovasc Intervent Radiol2022
35949288Real-World Data for Lenvatinib in Hepatocellular Carcinoma (ELEVATOR): A Retrospective Multicenter Study.Liver Cancer2022
36084663Hepatocellular carcinoma.Lancet2022
36051472Lenvatinib in patients with unresectable hepatocellular carcinoma who progressed to Child-Pugh B liver function.Ther Adv Med Oncol2022
35222353Immune Regulatory 1 Cells: A Novel and Potent Subset of Human T Regulatory Cells.Front Immunol2022
35251317Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience.Ther Adv Med Oncol2022
  • 1 - 50 of 279

Recommended Authors

Johannes Eschrich
Clinic for Hepatology and Gastroenterology, Charite University Medical Center
Career Start Year 2016
Number of shared co-authors 7
Khashayar Asadi
Austin Hospital
Career Start Year 2015
Number of shared co-authors 0
Meixiao Zhan
Zhuhai People's Hospital (Zhuhai Hospital Affiliated with Jinan University)
Career Start Year 2013
Number of shared co-authors 0
Yu Rim Lee
Kyungpook National University
Career Start Year 2010
Number of shared co-authors 1
Ligong Lu
Guangdong General Hospital, Guangdong Academy of Medical Sciences
Career Start Year 2007
Number of shared co-authors 1
Johannes Haybaeck
Institute of Pathology, Medical University of Innsbruck
Career Start Year 2007
Number of shared co-authors 2
Shu Zhang
The Second Affiliated Hospital of Xi'an Jiaotong University
Career Start Year 2007
Number of shared co-authors 0
Masahiko Tameda
Mie University Graduate School of Medicine
Career Start Year 2005
Number of shared co-authors 0
Qiyu Zhang
The First Affiliated Hospital of Wenzhou Medical University
Career Start Year 2002
Number of shared co-authors 0
Itzhak Avital
Goldman School of Medicine, Ben Gurion University
Career Start Year 2001
Number of shared co-authors 0
Scott Kopetz
University of Texas MD Anderson Cancer Center
Career Start Year 2000
Number of shared co-authors 1
Arief A Suriawinata
Dartmouth Hitchcock Medical Center
Career Start Year 1999
Number of shared co-authors 0
Ali Zarrinpar
College of Medicine, University of Florida
Career Start Year 1999
Number of shared co-authors 0
Eric A Collisson
University of California san francisco
Career Start Year 1999
Number of shared co-authors 1
Hye Won Lee
Yonsei University College of Medicine, Severance Hospital
Career Start Year 1998
Number of shared co-authors 1
Thomas J George
UF Health Cancer Center
Career Start Year 1998
Number of shared co-authors 0
Joon Oh Park
Samsung Medical Center, Sungkyunkwan University School of Medicine
Career Start Year 1997
Number of shared co-authors 1
Antonio Cubillo
Hospital HM Universitario Sanchinarro
Career Start Year 1997
Number of shared co-authors 0
John D Gordan
Quantitative Biosciences Institute (QBI), University of California San Francisco
Career Start Year 1996
Number of shared co-authors 1
Sung Tae Kim
Busan Paik Hospital, Inje University
Career Start Year 1996
Number of shared co-authors 1
Wells A Messersmith
University of Colorado Anschutz Medical Campus
Career Start Year 1995
Number of shared co-authors 0
Udo Rudloff
Center for Cancer Research, National Cancer Institute
Career Start Year 1994
Number of shared co-authors 1
Xin Wei Wang
Center for Cancer Research, National Cancer Institute (NCI)
Career Start Year 1994
Number of shared co-authors 5
Oliver F Bathe
Cumming School of Medicine, University of Calgary
Career Start Year 1991
Number of shared co-authors 0
Emile E Voest
The Netherlands Cancer Institute
Career Start Year 1989
Number of shared co-authors 2
Jose A Lopez-Martin
Hospital Universitario 12 de Octubre
Career Start Year 1988
Number of shared co-authors 0
Steven R Alberts
Mayo Clinic
Career Start Year 1987
Number of shared co-authors 2
Al B Benson
Northwestern University Feinberg School of Medicine
Career Start Year 1984
Number of shared co-authors 1
Richard D Schulick
University of Colorado School of Medicine
Career Start Year 1983
Number of shared co-authors 0
Antonio Jimeno
University of Colorado School of Medicine
Career Start Year 1974
Number of shared co-authors 1

Collaborators

Peter Schirmacher
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 15
Thomas Longerich
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 11
Celina Ang
Tisch Cancer Institute, Mount Sinai Hospital
Co-authored papers 8
Michael Ott
Co-authored papers 6
Andrew McQuillin
Co-authored papers 5
Stephanie Roessler
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 5
Albrecht Stenzinger
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 4
Andre Franke
Institute of Clinical Molecular Biology, Kiel University
Co-authored papers 3
Volker Endris
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 3
Tim F Greten
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Co-authored papers 3
Anna-Lena Volckmar
Institut fur Pathologie, Universitatsklinikum Heidelberg
Co-authored papers 2
Umut Ozbek
Co-authored papers 2
Stefan Fr??hling
German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT)
Co-authored papers 2
Frank Tacke
Charite-Universitatsmedizin Berlin
Co-authored papers 2
Marcella Rietschel
Central Institute of Mental Health, University of Mannheim
Co-authored papers 2
Lars Zender
Co-authored papers 2
Joseph E Aslan
Oregon Health & Science University
Co-authored papers 2
Ana Lleo
Humanitas University
Co-authored papers 2
Rohit Loomba
Co-authored papers 2
Sebastian Uhrig
National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ)
Co-authored papers 2
Thomas Albrecht
Institute of Pathology, Heidelberg University Hospital
Co-authored papers 2
Timo Gaiser
Institut fur Pathologie, Universitatsmedizin Mannheim
Co-authored papers 2
Masayuki Yamamoto
Tohoku University Graduate School of Medicine, Tohoku University
Co-authored papers 2
Timothy C Burn
Incyte Research Institute
Co-authored papers 2
Peter Horak
German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT)
Co-authored papers 1
Patrick J McKiernan
Children's Hospital of Pittsburgh
Co-authored papers 1
Siddharth Singh
University of California San Diego
Co-authored papers 1
Ido Amit
Weizmann Institute of Science
Co-authored papers 1
Martina Kirchner
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 1
Markus Riester
Novartis Institutes for BioMedical Research
Co-authored papers 1
Release 1.2